B
Bishal Gyawali
Researcher at Queen's University
Publications - 261
Citations - 16176
Bishal Gyawali is an academic researcher from Queen's University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 25, co-authored 194 publications receiving 10845 citations. Previous affiliations of Bishal Gyawali include State University of New York System & Kathmandu.
Papers
More filters
Journal ArticleDOI
Cancer care and research in India: what does it mean to Nepal?
Journal ArticleDOI
Reassessing the Net Benefit of Cancer Drugs With Evolution of Evidence Using the ASCO Value Framework.
Seanthel Delos Santos,Noah Witzke,Bishal Gyawali,Vanessa Sarah Arciero,Vanessa Sarah Arciero,Amanda Putri Rahmadian,Louis Everest,Matthew C. Cheung,Matthew C. Cheung,Kelvin K. W. Chan +9 more
TL;DR: In this article, the authors evaluated the ASCO-Value Framework (ASCO-VF) net health benefit at the time of approval and over time as further evidence arose.
Journal ArticleDOI
Prevalence of quality of life(QoL) outcomes and association with survival in cancer clinical trials.
Bishal Gyawali,Thomas J Hwang +1 more
TL;DR: This work investigated whether data reported in pivotal trials of new therapies in Oncology Outcomes Reviews (QoL) is representative of the true picture in patients and physicians in oncology care.
Journal ArticleDOI
Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis
Karolina Strzebonska,Mateusz Blukacz,Mateusz T. Wasylewski,Maciej Polak,Bishal Gyawali,Marcin Waligóra +5 more
TL;DR: In this article , a systematic review with meta-analysis was conducted to evaluate the efficacy and safety profiles in cancer umbrella trials testing targeted drugs or a combination of targeted therapy with chemotherapy.
Journal ArticleDOI
Repurposing non-cancer drugs for Breast Cancer? An emerging opportunity
TL;DR: Off-patent non-cancer drugs that are candidates for cancer repurposing are called “financial orphan drugs” (Sukhatme 2014) as they offer no return on investment and less scientific reward compared with new molecules.